Square Pharmaceuticals (SQUARE BD) received approval for oral Covid-19 pill along with four other companies in Bangladesh, with no product or pricing differentiation.
No immediate sign of export acceleration due to completion delay of Kenya plant, which targets to serve Common Market for Eastern and Southern Africa (Comesa) population of approximately 400 million.
Recent top and bottom-line growth are lagging peers. With no immediate catalyst seen, investors should avoid the stock.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.